Spark Biomedical — Posts

Completed Enrollment of Neonatal Opioid Withdrawal Syndrome clinical study. Targeting Q2 submission to FDA.

Spark completed its first trial for menstrual health where subjects used neurostimulation for 2 hours per day during menstruation. Participants saw a 55% reduction in blood loss, 25% reduction in cycle duration, 50% reduction in cramp pain and significant improvement in mood, anxiety, and quality of life.

CMS issues unique HCPCS Codes for Sparrow Ascent

Second generation wearable neurostimulation platform cleared for opioid withdrawal management. Reducing COGS by 75% over gen 1.

Spark Biomedical received $575,086.00 from DHA

Spark Biomedical received $574,689.19 from DHA

Spark Biomedical received $171,429.00 from Army